Posted by Michael Wonder on 11 Sep 2025
FDA files Corcept’s new drug application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer
10 September 2025 - Corcept Therapeutics today announced that the US FDA has accepted Corcept’s new drug application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has assigned a PDUFA date of 11 July 2026 for the application.
